<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90854">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02084953</url>
  </required_header>
  <id_info>
    <org_study_id>AI443-112</org_study_id>
    <nct_id>NCT02084953</nct_id>
  </id_info>
  <brief_title>Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blinded, Positive-Controlled, Placebo-Controlled, 3-Way Crossover Study to Determine the Electrocardiographic Effects of BMS-791325 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether BMS-791325 has an effect on the
      electrocardiogram (ECG) interval QT corrected for Fridericia's method (QTcF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Purpose: Other: This Phase 1 study is a clinical pharmacology thorough QT study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Difference from placebo of BMS-791325 in time-matched change from baseline (Day -1 on the study) to Day 3 of each period (ΔΔQTcF) at postdose extraction times for the QTcF</measure>
    <time_frame>Approximately 28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>ΔΔHR, ΔΔPR, ΔΔQRS, ΔΔQT</measure>
    <time_frame>Approximately 28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Difference from placebo in time-matched change from baseline (Day -1) to Day 3 at postdose extraction times in the ECG-derived RR or HR and other ECG intervals (PR, QRS, QT). QT is the unadjusted QT interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percent of subjects having a within-period maximum HR, PR, QRS, QT, QTcF, ΔQT and ΔQTcF within prespecified categories</measure>
    <time_frame>Approximately 28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between plasma concentrations of BMS-791325, BMS-794712, and BMS-948158, and the corresponding ΔΔQTcF</measure>
    <time_frame>Approximately 28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of BMS-791325, BMS-794712, and BMS-948158</measure>
    <time_frame>43 timepoints up to day 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentration (Tmax) of BMS-791325, BMS-794712, and BMS-948158</measure>
    <time_frame>43 timepoints up to day 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval (AUC(TAU)) of BMS-791325, BMS-794712, and BMS-948158</measure>
    <time_frame>43 timepoints up to day 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total oral clearance (CLT/F) of BMS-791325, BMS-794712, and BMS-948158</measure>
    <time_frame>43 timepoints up to day 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal phase plasma half life (T-HALF) of BMS-791325, BMS-794712, and BMS-948158</measure>
    <time_frame>43 timepoints up to day 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(TAU) metabolic ratios of BMS-791325, BMS-794712, and BMS-948158</measure>
    <time_frame>43 timepoints up to day 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs, SAEs, AEs leading to discontinuation and death, marked laboratory abnormalities, findings on 12-lead safety ECG measurements and physical examination, and abnormalities in vital sign measurements exceeding pre-defined thresholds</measure>
    <time_frame>Up to  day 28</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse event (AEs)
Serious adverse event (SAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference from placebo of Moxifloxacin in change from baseline (Day -1) to Day 3 at postdose extraction times for the QTcF (ΔΔQTcF)</measure>
    <time_frame>Approximately 28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>ARM A: BMS-791325</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-791325 600 mg tablet orally on 1st and 2nd day, then 900 mg on the 3rd day once a day for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B: Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moxifloxacin 400mg tablet orally once on third day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM C: Placebo matching BMS-791325</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching BMS-791325 0 mg tablet orally once daily for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-791325</intervention_name>
    <arm_group_label>ARM A: BMS-791325</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <arm_group_label>ARM B: Moxifloxacin</arm_group_label>
    <other_name>Avelox®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching BMS-791325</intervention_name>
    <arm_group_label>ARM C: Placebo matching BMS-791325</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Healthy men and women, ages 18 to 49 yr old

          -  BMI 18 to 32

          -  Women must not be pregnant or breastfeeding

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  A personal history of clinically relevant cardiac disease, symptomatic or
             asymptomatic arrhythmias, presyncope or syncopal episodes, or additional risk factors
             for torsades de pointes (eg, heart failure)

          -  History of hypokalemia, personal history or family history of prolonged QT interval,
             or family history of sudden cardiac death at a young age

          -  History of biliary disorders, including Gilbert's disease or Dubin-Johnson disease

          -  Inability to swallow multiple tablets consecutively

          -  Any of the following on 12-lead electrocardiogram (ECG) prior to study drug
             administration: PR ≥ 210 msec, QRS ≥ 120 msec, QT ≥ 500 msec, QTcF ≥ 450 msec, Heart
             Rate (HR) &lt; 45 bpm

          -  Second or third degree heart block prior to study drug

          -  Positive urine screen for drugs of abuse

          -  Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or Human
             Immunodeficiency Virus (HIV)-1, -2 antibody

          -  Any of the following lab results outside of the ranges specified below prior to
             dosing:  Alanine aminotransferase (ALT) &gt; upper limit of normal (ULN), Aspartate
             aminotransferase (AST) &gt; ULN, Total bilirubin &gt; ULN, Direct bilirubin &gt; ULN,
             Creatinine &gt; ULN,  Serum potassium &lt; lower limit of normal (LLN), Serum magnesium &lt;
             LLN

          -  History of allergy to Moxifloxacin, BMS-791325, nonstructural protein 5B (NS5B)
             non-nucleoside inhibitors or related compounds
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ppd Development, Llc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas L Hunt, Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>March 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
